Is the Addition of Chemotherapy to Adjuvant Radiation in Merkel Cell Cancer Beneficial? Real-World Data with Long-Term Follow-Up
Authors:
- Walid ShalataWalid Shalata
- Hanna T. Frumin EdriHEHanna T. Frumin Edri
- Ina SarelISIna Sarel
- Anna IevkoAIAnna Ievko
- Sofiia TuraievaSTSofiia Turaieva
- Tanzilya TairovTTTanzilya Tairov
- Ilia BerezhnovIBIlia Berezhnov
- Shlomit FenigSFShlomit Fenig
- Eyal FenigEFEyal Fenig
- Tomer Ziv-BaranTZTomer Ziv-Baran
- Alexander YakobsonAYAlexander Yakobson
- Ronen BrennerRBRonen Brenner
Open Access
Abstract
Background: The role of adding chemotherapy to adjuvant radiation therapy in resectable Merkel cell carcinoma (MCC) remains controversial. Previous studies have shown conflicting results, and long-term outcome data are limited. Objectives: In this study, we aimed to evaluate the long-term survival outcomes of patients with resectable MCC treated with surgery followed by either radiation alone or combined chemoradiation. Methods: This retrospective multicenter cohort study analyzed 105 patients with resectable MCC treated between 1985 and 2023. Patients received either adjuvant radiation alone (n = 53) or chemoradiation (n = 52) following surgery. The primary endpoints were overall survival and disease-free survival. The secondary endpoints included an analysis of prognostic factors and treatment-related characteristics. The median follow-up was 12 years. Results: The 20-year overall survival rates were 53.4% for chemoradiation versus 30.7% for radiation alone (p = 0.324). Median survival in the chemoradiation groups was not reached during the follow-up period; in the radiation group, it was 8.8 years. Likewise, the twenty-year disease-free survival rates were not significantly different between the chemoradiation and radiation groups: 47% vs. 29.3%, respectively, p = 0.495. The chemoradiation group had significantly more advanced disease (88% vs. 28.3% stage III) but was younger (median 65.9 vs. 77.3 years, p = 0.002) and received higher radiation doses (median 50 Gy vs. 45 Gy, p = 0.002). After controlling for age, stage, and tumor location in a multivariable analysis, the survival differences were still not significantly different (hazard ratio (HR) = 1.36, 95% CI 0.61–3.00, p = 0.450). Conclusions: While the multivariate analysis did not indicate a survival advantage to adding chemotherapy to radiation, the comparable survival outcomes despite significantly more advanced disease in the chemoradiation group suggest a possible benefit in high-risk patients. Our results indicate the need for prospective studies with larger, stage-matched cohorts to definitively establish the role of adjuvant chemotherapy in high-risk resectable MCC.Keywords
This publication has 31 references indexed in Scilit:
- Oncologic outcomes of patients with Merkel Cell Carcinoma (MCC): A multi-institutional cohort studyThe American Journal of Surgery, 2021
- Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell CarcinomaJAMA Oncology, 2018
- Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMECCancer Immunology, Immunotherapy, 2017
- Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needsEuropean Journal of Cancer, 2017
- Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinomaCancer Medicine, 2016
- The Role of Adjuvant Therapy in the Management of Head and Neck Merkel Cell CarcinomaJAMA Otolaryngology–Head & Neck Surgery, 2015
- Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinomaCancer, 2011
- Adjuvant Local Irradiation for Merkel Cell CarcinomaArchives of Dermatology, 2006
- Merkel cell carcinoma: Changing incidence trendsJournal of Surgical Oncology, 2004
- The role of radiation therapy and chemotherapy in the treatment of merkel cell carcinomaCancer, 1997